Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion.

Research output: Contribution to journalArticle


  • Laurent Garderet
  • Dimitris Ziagkos
  • Anja Van Biezen
  • Simona Iacobelli
  • Jürgen Finke
  • Johan Maertens
  • Liisa Volin
  • Per Ljungman
  • Patrice Chevallier
  • Jakob Passweg
  • Nicolaas Schaap
  • Dietrich Beelen
  • Arnon Nagler
  • Didier Blaise
  • Xavier Poiré
  • Ibrahim Yakoub-agha
  • Stig Lenhoff
  • Rik Schots
  • Alessandro Rambaldi
  • Jaime Sanz
  • Pavel Jindra
  • Ghulam J. Mufti
  • Marie Robin
  • Nicolaus Kröger

Colleges, School and Institutes


The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.


Original languageEnglish
Pages (from-to)507-513
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Issue number3
Early online date28 Nov 2017
Publication statusPublished - Mar 2018


  • MDS, del (5q), Allogeneic stem cell transplantation